You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Idiopathic pulmonary fibrosis or not: antibiotic prophylaxis for all patients on immunosuppressants
  1. Manuel L Ribeiro Neto1,
  2. Jeffrey J Swigris2,
  3. Daniel A Culver1
  1. 1 The Cleveland Clinic Foundation, Respiratory Institute, Cleveland, Ohio, USA
  2. 2 Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, Colorado, USA
  1. Correspondence to Dr Manuel L Ribeiro Neto, The Cleveland Clinic Foundation, Respiratory Institute, 9500 Euclid Avenue/A90, Cleveland, OH 44195, USA; ribeirm{at}ccf.org

https://doi.org/10.1136/thoraxjnl-2013-203395

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Shulgina et al 1 reported the effects of co-trimoxazole on outcomes in fibrotic idiopathic interstitial pneumonia (IIP). We have some concerns about their conclusions and the emphasis of their findings.

    With nearly half (43%) of subjects taking ≥10 mg of prednisolone daily, a dose that increases infection risk,2 and over 30% taking a steroid-sparing agent, a valid alternate explanation for their results is that the beneficial effects of co-trimoxazole were due to prevention of adverse effects of immunosuppressive drugs. The occurrence of fewer pneumonias …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles